Loading organizations...
§ Private Profile · 300 Mission Bay Blvd South San Francisco, CA 94158
Rezo Therapeutics is a technology company.
Rezo Therapeutics develops precision therapeutics through an integrated discovery platform. This platform leverages distinct technologies and artificial intelligence to map disease networks comprehensively. Their approach identifies novel therapeutic targets and employs small molecules to modulate protein activity or detect disease-relevant mutations, aiming to advance drug development.
Co-founded in 2022 by University of California, San Francisco scientists, including Nevan Krogan, Natalia Jura, Sourav Bandyopadhyay, Kevan Shokat, Norbert Bischofberger, George Scangos, and Jacqueline Fabius, Rezo Therapeutics originated from a key insight. Dr. Krogan’s pioneering work on an integrated disease network mapping platform offered a novel way to transform therapeutic target identification and drug discovery.
The company targets critical unmet medical needs, ultimately benefiting patients across diverse therapeutic areas. Rezo Therapeutics' vision is to significantly enhance the success rate of drug development. It seeks to establish a new paradigm for identifying and treating diseases through a more precise and effective approach to medicine.
Rezo Therapeutics has raised $78.0M across 1 funding round.
Rezo Therapeutics has raised $78.0M in total across 1 funding round.
Rezo Therapeutics has raised $78.0M across 1 funding round. Most recently, it raised $78.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $78M Series A | Andreessen Horowitz, SR ONE, A16z Scout Fund, Norwest Venture Partners | HBM Partners, OrbiMed, Section 32, Vivo Capital, Hawktail, Liquid 2 Ventures, SV Angel | Announced |
Rezo Therapeutics is a San Francisco-based biotechnology company developing precision medicines by mapping disease-related protein networks to identify novel drug targets, primarily in oncology and other serious diseases.[1][2][3] It builds an integrated Sequence to Systems to Drugs (SSD) platform that combines proteomics, genetics, structural biology, chemistry, and bioinformatics with AI to analyze genomic data, uncover tumor-specific targets, and accelerate therapies from discovery to clinical candidates.[1][2][3] The company serves patients with solid tumors and plans to expand into additional areas via partnerships, solving the problem of traditional drug discovery's slowness and silos by targeting overlooked protein-protein interactions.[2][3] Launched in 2022 with $78 million in Series A funding led by SR One, a16z Bio + Health, and Norwest Venture Partners, Rezo shows growth momentum through leadership additions, including CEO Derek Hicks in August 2025 (with 25+ years at Intellia, Spark, and Pfizer) and earlier CEO Nadir Mahmood.[2][3][4]
Rezo Therapeutics emerged from research at the Quantitative Biosciences Institute (QBI) at UCSF, founded by renowned UCSF scientists including co-founder and board chairman George Scangos, Ph.D., who emphasized shifting drug discovery through analysis of protein-protein, genetic, and biochemical interactions.[3] The idea stemmed from integrating unbiased technologies to map "networks that go awry in disease," starting with oncology where mutations rewire cancer-driving pathways.[1][3] Pivotal early traction came with its November 17, 2022 launch and $78 million Series A financing, enabling rapid pipeline advancement in solid tumor oncology with mutation-specific biomarkers.[3] Leadership evolved with Nadir Mahmood, Ph.D., as initial CEO (from Nkarta), succeeded by Derek Hicks in 2025 to drive business development and commercialization.[2][4]
Rezo stands out in biotech through its tech-driven, integrated approach:
Rezo rides the AI-biotech convergence trend, leveraging computational tools to decode complex disease networks amid rising demand for precision oncology amid cancer's global burden.[1][2][3] Timing aligns with post-2022 AI advancements and proteomics/genomics data explosions, favoring network-based discovery over single-target hunts, especially as traditional methods fail "undruggable" interactions.[2][3] Market forces like biomarker-driven trials and VC interest in platform tech (evident in its Series A) propel it, while UCSF origins tap elite talent networks.[3] Rezo influences the ecosystem by pioneering "systems biology" drugging, potentially inspiring collaborations and shifting paradigms from reductionist to holistic models.[3]
Rezo is primed to advance its oncology pipeline toward clinical trials, with new CEO Derek Hicks accelerating partnerships and commercialization.[2] Trends like AI-enhanced multi-omics and allele-specific therapies will shape its path, expanding beyond tumors into immunology or neurodegeneration via alliances.[1][3] Its influence may grow by licensing network maps or SSD tech, redefining biotech efficiency—echoing its launch promise to "unlock a new era of drug discovery" through mapped disease networks.[3][5]
Rezo Therapeutics has raised $78.0M in total across 1 funding round.
Rezo Therapeutics's investors include Andreessen Horowitz, SR One, Norwest Venture Partners, Hbm Partners, OrbiMed, Section 32, Vivo Capital, Hawktail, Liquid 2 Ventures, SV Angel.